Publisher
Springer International Publishing
Reference52 articles.
1. Taskinen MR, Kahri J, Koivisto V, Shepherd J, Packard CJ. Metabolism of HDL apolipoprotein A-I and A-II in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(4):347–56.
2. Dullaart RPF. Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med. 1995;46(1):44–54.
3. Nobécourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2010;30(4):766–72.
4. Tóth PP. An urgent matter-identifying your patients’ cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease. J Fam Pract. 2009;58(11 Suppl Urgent):S19–25.
5. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem. 1995;270(18):10828–32.